Indications and Long-Term Outcomes of Using Mycophenolate Mofetil Monotherapy in Substitution for Calcineurin Inhibitors in Liver Transplantation
Transplant International · 2025
DOI: 10.3389/ti.2025.13790 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, 2025. Verfasst von Carlos Jiménez-Romero und 10 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Hepato-Pancreato-Biliary Surgery and Abdominal Organ Transplantation, Doce de Octubre University Hospital, Madrid, Spain. Hauptthemen laut MEDLINE: Liver Transplantation, Mycophenolic Acid, Calcineurin Inhibitors, Immunosuppressive Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Switching the use of calcineurin inhibitors (CNIs), as basal immunosuppression in liver transplantation (LT) patients, for that of mycophenolate mofetil monotherapy (MMF-MT) is currently considered a good measure in recipients with chronic kidney disease (CKD) and other CNI-related adverse effects. We analyzed a retrospective cohort series of 324 LT patients who underwent long-term follow-up and were switched from CNI immunosuppression to MMF-MT due to CKD and other CNI-related adverse effects (diabetes, hypertension, infection). The median time on MMF-MT was 78 months. The indication for MMF-MT was CKD alone or associated with CNI-related adverse effects in 215 patients, diabetes in 61, hypertension in 42, and recurrent cholangitis in 6. Twenty-four (7.4%) patients developed non-resistant acute rejection post-MMF-MT, and 48 (14.8%) patients experienced MMF-related adverse effects, with MMF-MT withdrawn in only 8 (2.5%) patients. In the comparison between the pre-MMF-MT period and the last outpatient review, using a repeated measures model and taking each patient as its own comparator, we demonstrated a significant increase in GFR and significant decrease in creatinine and ALT values, remaining the other variables (diabetes, hypertension, and hematological and AST) within similar levels. Five-year survival post-MMF-MT conversion was 75.3%. MMF-MT significantly improved renal function, was well tolerated, and had a low rejection rate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Hepato-Pancreato-Biliary Surgery and Abdominal Organ Transplantation, Doce de Octubre University Hospital, Madrid, Spain.
- Department of Surgery, Faculty of Medicine, Complutense University, Madrid, Spain.
- Clinical Research Department, Instituto de Investigación (imas12), Madrid, Spain.
Zitieren
APA
Jiménez-Romero, C., Justo Alonso, I., Caso Maestro, O., Manrique Municio, A., García-Sesma, Á., Calvo Pulido, J., Cambra Molero, F., Loinaz Segurola, C., Martín-Arriscado, C., Nutu, A., & Marcacuzco Quinto, A. (2025). Indications and Long-Term Outcomes of Using Mycophenolate Mofetil Monotherapy in Substitution for Calcineurin Inhibitors in Liver Transplantation. Transplant International. https://doi.org/10.3389/ti.2025.13790
Vancouver
Jiménez-Romero C, Justo Alonso I, Caso Maestro O, Manrique Municio A, García-Sesma Á, Calvo Pulido J, et al. Indications and Long-Term Outcomes of Using Mycophenolate Mofetil Monotherapy in Substitution for Calcineurin Inhibitors in Liver Transplantation. Transplant International. 2025. doi:10.3389/ti.2025.13790
BibTeX
@article{JimnezRomero2025,
author = {Jiménez-Romero, Carlos and Justo Alonso, Iago and Caso Maestro, Oscar and Manrique Municio, Alejandro and García-Sesma, Álvaro and Calvo Pulido, Jorge and Cambra Molero, Félix and Loinaz Segurola, Carmelo and Martín-Arriscado, Cristina and Nutu, Anisa and Marcacuzco Quinto, Alberto},
title = {Indications and Long-Term Outcomes of Using Mycophenolate Mofetil Monotherapy in Substitution for Calcineurin Inhibitors in Liver Transplantation},
journal = {Transplant International},
year = {2025},
doi = {10.3389/ti.2025.13790}
}
EUVIMED